OTLK Outlook Therapeutics Inc

$OTLK I have a feeling we are all going to be in for a big surprise, with a better than expected event, such as a partnership or licensing deal, sales goals exceeded, meaningful restriction or enforcement against 503B compounded bevacizumab, etc, that quickly and dramatically re-rates the stock and share price. And I was the one who believed the FDR would result in a reversal of the CRL, which almost never happens. What I mean by that is the near impossible happened already, but the events I described above are not even close to near impossible. I put my money where my mouth is Buster 

$OTLK just sold five MSFT shares and bought 5000 OTLK shares. Let's see if it will be worth it!

$OTLK It currently looks like all you need for another green day is hope and potential, no product revenue, not even a BLA submission. Just look at KOD: positive Phase 3 data and a planned BLA filing are enough to fuel optimism, that’s currently enough for a $5.3B market cap. Meanwhile, OTLK has a commercial launch approaching, yet apparently that’s only worth another red day and not even a measly $140M market cap. Both KOD and OTLK target the same massive retina market, with overlapping potential in wet AMD. That's biotech. LOL 😉

$OTLK I could list countless milestones already achieved and still to come, but I’ll use just one word UNDERVALUED!

$OTLK Absolutely insane! SLS has $138.3M in cash but still needs final Phase 3 REGAL results before a potential BLA. KOD has $125.9M in cash, no product revenue and hasn’t even filed its BLA for Zenkuda, planned for Q4 2026. KOD even targets the same retina market as $OTLK , while SLS operates in oncology, a completely different field. Yet both command multi-billion-dollar valuations based largely on future hopes. Meanwhile, $OTLK raised $51.1M in net proceeds from its August offering and already has an FDA-approved product, initial European sales and a US launch ahead. Yes, commercialization, reimbursement and funding remain challenges. But why is speculative pipeline potential worth billions for SLS and KOD, while OTLK’s approved product and commercial opportunity receive so little recognition? All three carry risks, but $OTLK is clearly further along the path to commercialization. This valuation gap is absolutely ridiculous, in my view 👀

$OTLK I think people are making a big mistake by focusing too much on the $485 WAC. I’m convinced the REAL commercial pricing strategy will be far more aggressive. Discounts, rebates, payer negotiations, launch programs and access incentives can push the effective net price much lower than the headline number. If management truly wants LYTENAVA to attack Avastin’s entrenched position, they need adoption and volume — not just a high sticker price. The market may be seriously underestimating how disruptive this launch strategy could become. 👀🔥

$OTLK you know something big is coming, you’ve been humbled enough, now i’s the right time to boost.

$OTLK share price is getting higher and higher, hope accumulation is done and we’re about to get the news launch soon

$OTLK The launch cannot be that far off. My hope is we get some license deal at the same time. If this can burn through that 55 million share overhang with a good run because of those two things this would be golden. Plenty of cash and proof someone really believes in it.

$OTLK I believe LYTENAVA’s U.S. launch could be just weeks away, potentially in November! The pieces are falling into place: J-code application submitted, commercial leadership strengthened, and reimbursement and distribution preparations underway. But here's what could really surprise the market: a launch backed by strong insurance coverage and a much more aggressive net pricing strategy than the $485 WAC suggests. If Outlook delivers that combination, the market reaction could be explosive. 💥 The real catalyst isn't just the launch date. It's the commercial strategy behind it. $1.X could be closer than many think. 🔥

$OTLK The AMD drug market is estimated at roughly $10B-$12B+ globally and growing, with North America representing the largest regional share. A single product, Eylea, generated an estimated $11.15 billion global market value in 2026 according to industry market reports covering Eylea-related sales and market activity.OTLK is not trying to replace Eylea or Vabysmo completely. Its opportunity is mainly in the massive off-label bevacizumab segment: Many retina specialists already use bevacizumab because it is much cheaper. LYTENAVA™ is the first FDA-approved ophthalmic bevacizumab formulation. If physicians switch from compounded bevacizumab to FDA-approved LYTENAVA, OTLK could capture meaningful revenue without needing dominant market share. Back-of-the-Envelope OTLK Scenarios If LYTENAVA captures: 1% of a ~$10B market → roughly $100M/year opportunity 2% → roughly $200M/year 5% → roughly $500M/year

$OTLK Give us some meaningful volume! Until then I can't get excited about these pennies.

$OTLK My take on it : October- November : 0.58-0.88 December-January: Official launch, syringes hit clinics, Q4 2026 financial reports 1.20-1.85 April-MayPermanent J-code becomes active, first actual revenue reports 2.5-4.00 if successful Your call.

$OTLK These pirates painted the close at $0.52, but the accumulation pattern looks crystal clear to me. Strong hands are loading up while they try to shake out retail. The next few trading days should tell the story. Buy as much as you can afford! 🚀

$OTLK • May 19: Intraday low of $0.2150 • June 22: Intraday high of $1.88 • That is a move of roughly +775% in about 5 weeks. That was the result of the FDR win, which still carried the risk of another CRL This shows you how quickly it can move, so don’t let today’s share price bother you.

$OTLK ssssh silent. they are not done yet accumulating shares, remember insiders bought at 0.99 per share, you buy at a discount now.

$OTLK I have been observing today's action and I believe we are cooking or the big whales know something that we don't yet. I added additional 1000 shares to my position of already 7.500. Looking to make it 10.000! Finally volume seem to grow, and the selling pressure was almost non-existent. Level 2 data was showing that at some point buy orders for $0.01 under market were removed, because simply noone was filling them!

$OTLK my intuition and not advice .. .. the markets could very well see a November/December much like 2018 if you were around trading then. ....

$OTLK Very important for OTLK!!!!!!! EyePoint is not only claiming that LUCIA failed to meet its target. The company is prematurely ending the LUGANO and LUCIA clinical trials for wet age-related macular degeneration (wet AMD), without completing the second year of follow-up, and cutting approximately 53% of its workforce. The restructuring is expected to generate savings of approximately $30 million annually, a one-time severance cost of about $9 million, and the reallocation of the remaining resources to the DURAVYU program for diabetic macular edema (DME). So, while management states that it will "evaluate next steps" in the field of wet AMD, its actions speak louder than words: operationally, the wet AMD program has been suspended indefinitely. For OTLK, this is far more important than the statistical details of the trial.

$OTLK Plenty of room to run. No need for possible reverse split until March and then an extension to October would be highly likely. This won’t be this low for long.